Sylics was acquired by InnoSer. To see what’s new, read below or use the navigation bar to find the information you need.

    Ageing

    Investigate relevant molecular compounds to promote increased human longevity and healthy ageing thanks to our experience with naturally aged mice  

    Aging represents the accumulation of changes over time and generally increases the risk of a wide range of diseases, such as inflammatory and neurodegenerative diseases. Compounds that target the aging process may therefore have broad therapeutic applications.    

    Aging is, however, a complex process in which all tissues in the body change over time. Given the multitude of potential causes of aging, it is challenging to find a good model system for this process. Therefore, the most holistic, agnostic, and straightforward method is to let wild-type mice age naturally over time.  

    At InnoSer, we have access to aged cohorts of C57BL/6J (B6) mice up to 2 years of age. We additionally perform experiments in mouse models with pathologies associated with aging, such as models of Aβ plaque pathology, tau pathology, and natural aging. Histological staining for p16 (i.e., p16INK4A) and β-gal (β-galactosidase) is used to assess senescence at InnoSer.

    Take advantage of InnoSer’s expertise in modelling the ageing pathology. Our in-house neurology experts are happy to help guide your decision on study design fit for your current research goals. 

    Aged mice model key characteristics:

    • Aged mice are available up to 2 years of age. 
    • By 22 months of age, mice display profound changes in behaviour, different from changes seen in neurodegeneration models, such as decreased activity and velocity in the PhenoTyper™

    Find the right model for you.

    Compare our model capabilities and discover which of our neurology platforms suits your research needs

    Belgian based preclinical neurology CRO mouse models

    Key readouts

    Test the efficacy of your treatments in the following battery of cognitive behavioural tests: 

    Test the efficacy of your treatments with the following biological readouts:

    • IHC: senescence markers (p16INK4A; β-gal)

    Related model options

    Neurology Platform Overview

    Highly relevant neurology models to facilitate preclinical drug development

    Alzheimer's Disease

    Complimentary range of models and unique behavioural services that recapitulate key characteristics of Alzheimer’s Disease in vivo.

    Parkinson's Disease

    InnoSer offers unique behavioral services using in vivo models such as MPTP, 6-OHDA induced models, but also genetic (GBA, LRKK2) and alpha-synuclein (both transgenic and seeding).

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

    Need more information?

    If you have any questions about how we can help accelerate your research,

    then let us know